Download PDF
Fortschr Neurol Psychiatr 2004; 72(9): 503-515
DOI: 10.1055/s-2003-812459
Originalarbeit
© Georg Thieme Verlag Stuttgart · New York

Flunitrazepam und Fahrtüchtigkeit

Eine kritische Analyse relevanter StudienFlunitrazepam and Driving Ability A Critical Analysis of Relevant Studies R.  M.  Kaufmann1 , R.  Frey1 , H.  J.  Battista2 , S.  Kasper1
  • 1Klinische Abteilung für Allgemeine Psychiatrie, Universitätsklinik für Psychiatrie, Wien (Leiter: O. Univ.-Prof. Dr. Dr. h. c. S. Kasper)
  • 2Gerichtlich beeideter Sachverständiger für allgemeine Chemie, Pharmakologie und Toxikologie und Gerichtliche Medizin, Innsbruck
Further Information

Publication History

Publication Date:
30 August 2004 (online)

    Permissions and Reprints

Zusammenfassung

Neben epidemiologischen Studien tragen vor allem experimentelle Studien dazu bei, den Einfluss von Medikamenten auf die Fahrtüchtigkeit zu erforschen. Da die Ergebnisse einer einzelnen Studie wesentlich durch das experimentelle Design determiniert sind, kann eine fundierte Einschätzung des Risikos einer Medikamenteneinnahme in Bezug auf die Fahrtüchtigkeit weder anhand einer einzelnen Studie noch anhand von Stellungnahmen, die nur wenige Studien ohne detaillierte Informationen erfassen, erfolgen. Diese Arbeit stellt eine Übersicht über veröffentlichte Studien dar, die sich direkt oder indirekt mit dem Einfluss von Flunitrazepam auf die Fahrtüchtigkeit beschäftigen, da besonders Benzodiazepine und unter ihnen speziell Flunitrazepam mit einer Beeinträchtigung der Fahrtüchtigkeit in Zusammenhang gebracht werden. Es wird versucht, besonders auf die Unterschiede hinsichtlich der verwendeten Dosierungen, experimentellen Designs und Testmethoden einzugehen. Übersichtshalber ist die Arbeit über Flunitrazepam deshalb in Akutwirkung, Residualwirkung und Wirkung nach subchronischer Applikation untergliedert. Es wurden unterschiedliche Ergebnisse berichtet, wobei aufgrund mangelnder Einheitlichkeit der Studien keine statistische Analyse im Sinne einer Metaanalyse durchgeführt wurde.

Abstract

Major contributions to the investigation of the influence of drugs on driving ability come from experimental studies as apart from epidemiological studies. Regarding experimental studies, the results of a single study are essentially determined by the experimental design. An established assessment of the risk of a drug in regard to driving ability should not be based on either a single study or on synopses, which record only a few studies without detailed information. This article presents an overview of published studies that directly or indirectly deal with the influence of flunitrazepam on driving ability. Benzodiazepines in particular, and amongst these especially flunitrazepam are brought into connection with the impairment of driving ability. This approach emphasises differences regarding the dosages used, the experimental designs and the methods of testing. For reasons of clarity the article on flunitrazepam is subdivided into the topics of acute effects, residual effects, and effects after subchronic application. Different results are reported. A statistical analysis in terms of a metaanalysis was not carried out due to a lack of standardization of the studies.

Literatur

  • 1 Woods J H, Winger G. Abuse liability of Flunitrazepam.  J Clin Psychopharmacol. 1997;  17 (Suppl. 2) 1S-57S
    PubMedGoogle Scholar
  • 2 Busto U, Bendayan R, Sellers E M. Clinical pharmacokinetics of non-opiate abused drugs.  Clin Pharmacokinet. 1989;  16 1-26
    PubMedGoogle Scholar
  • 3 Jochemsen R, Breimer D D. Pharmacokinetics of benzodiazepines: metabolic pathways and plasma level profiles.  Curr Med Res Opin. 1984;  8 60-79
    PubMedGoogle Scholar
  • 4 Owen R T, Tyrer P. Benzodiazepine dependence: a review of the evidence.  Drugs. 1983;  25 385-398
    PubMedGoogle Scholar
  • 5 Farré M, Terán M T, Camí J. A comparison of the acute behavioural effects of flunitrazepam and triazolam in healthy volunteers.  Psychopharmacology. 1996;  125 1-12
    PubMedGoogle Scholar
  • 6 Farré M, Terán M T, Roset P N, Mas M, Torrens M, Camí J. Abuse liability of flunitrazepam among methadone-maintained patients.  Psychopharmacology. 1998;  140 486-495
    CrossrefPubMedGoogle Scholar
  • 7 Keup W. Flunitrazepam (Rohypnol) - führend beim Missbrauch unter den Benzodiazepin-Derivaten.  Sucht. 1992;  38 3-6
    PubMedGoogle Scholar
  • 8 Barnas C, Rossmann M, Rössler H, Reimer Y, Fleischhacker W W. Benzodiazepines and other psychotropic drugs abused by patients in a methadone maintenance program: familiarity and preference.  J Clin Psychopharmacol. 1992;  12 397-402
    PubMedGoogle Scholar
  • 9 Navaratnam V, Foong K. Adjunctive drug use among Opiate addicts.  Curr Med Res Opin. 1990;  11 611-619
    PubMedGoogle Scholar
  • 10 San L, Tato J, Torrens M, Castillo C, Farré M, Cami J. Flunitrazepam consumption among Heroin addicts admitted for inpatient detoxification.  Drug Alcohol Depend. 1993;  32 281-286
    PubMedGoogle Scholar
  • 11 Calhoum S R, Wesson D R, Galloway G P, Smith D E. Abuse of Flunitrazepam (Rohypnol) and other benzodiazepines in Austin and South Texas.  J Psychoact Drugs. 1996;  28 183-189
    PubMedGoogle Scholar
  • 12 Krüger H P, Schulz E, Magerl H. Medikamenten- und Drogennachweis bei verkehrsunauffälligen Fahrern, Roadside Survey. Berichte der Bundesanstalt für Straßenwesen, Mensch und Sicherheit. 1996: Heft M 60
    Google Scholar
  • 13 Augsburger M, Rivier L. Drugs and alcohol among suspected impaired drivers in Canton de Vaud (Switzerland).  Forensic Sci Int. 1997;  85 95-104
    CrossrefPubMedGoogle Scholar
  • 14 Lillesunde P, Korte T, Michelson L, Portman M, Pikkarainen J. Drugs usage of drivers suspected of driving under the influence of alcohol and/or drugs. A study of one week's samples in 1979 and 1993 in Finland.  Forensic Sci Int. 1996;  77 119-129
    CrossrefPubMedGoogle Scholar
  • 15 Skurtveit S, Christophersen A S, Morland J. Female drivers suspected for drunken or drugged driving.  Forensic Sci Int. 1995;  75 139-148
    CrossrefPubMedGoogle Scholar
  • 16 Barbone F, McMahon A D, Davey P G, Morris A D, Reid I C, McDevitt D G, MacDonald T M. Association of road-traffic accidents with Benzodiazepine use.  Lancet. 1998;  353 1331-1336
    PubMedGoogle Scholar
  • 17 Currie D, Hashemi K, Fothergill J, Findlay A, Harris A, Hindmarch I. The use of antidepressants and benzodiazepines in the perpetrators and victims of accidents.  Occup Med (Lond). 1995;  45 323-325
    PubMedGoogle Scholar
  • 18 Neutel C I. Risk of traffic accident injury after a prescription for a benzodiazepine.  Ann Epidemiol. 1995;  5 239-244
    CrossrefPubMedGoogle Scholar
  • 19 Fortenberry J C, Brown D B, Shevlin L T. Analysis of drug involvement in traffic fatalities in Alabama.  Am J Drug Alcohol Abuse. 1986;  12 257-267
    PubMedGoogle Scholar
  • 20 Gjerde H, Beylich K M, Morland J. Incidence of alcohol and drugs in fatally injured car drivers in Norway.  Accid Anal Prev. 1993;  25 479-483
    CrossrefPubMedGoogle Scholar
  • 21 Mercer G W, Jeffery W K. Alcohol, drugs, and impairment in fatal traffic accidents in British Columbia.  Accid Anal Prev. 1995;  27 335-343
    CrossrefPubMedGoogle Scholar
  • 22 Druid H, Holmgren P, Ahlner J. Flunitrazepam: an evaluation of use, abuse and toxicity.  Forensic Sci Int. 2001;  122 136-141
    CrossrefPubMedGoogle Scholar
  • 23 Honkanen R, Ertama L, Linnoila M, Alha A, Lukkaria I, Karlsson M, Kiviluoto O, Puro M. Role of drugs in traffic accidents.  Br Med J. 1980;  281 1309-1312
    PubMedGoogle Scholar
  • 24 Thomas R E. Benzodiazepine use and motor vehicle accidents: Systematic review of reported association.  Can Fam Physican. 1998;  44 799-808
    PubMedGoogle Scholar
  • 25 Bocca M L, Le Doze F, Etard O, Pottier M, L'Hoste J, Denise P. Residual effects of zolpidem 10 mg and zopiclone 7.5 mg versus flunitrazepam 1 mg and placebo on driving performance and ocular saccades.  Psychopharmacology. 1999;  143 373-379
    CrossrefPubMedGoogle Scholar
  • 26 Gerhard U, Linnenbrink N, Georghiadou C, Hobi V. Vigilanzmindernde Effekte zweier pflanzlicher Schlafmittel.  Schweizer Rundschau für Medizin (Praxis). 1996;  85 473-481
    PubMedGoogle Scholar
  • 27 Harrison C, Subhan Z, Hindmarch I. Residual effects of zopiclone and benzodiazepine hypnotics on psychomotor performance related to car driving.  Drugs Exp Clin Res. 1985;  XI 823-829
    PubMedGoogle Scholar
  • 28 Vermeeren A, O'Hanlon J F, DeClerk A C, Kho L. Acute effects of zolpidem and flunitrazepam on sleep, memory and driving performance, compared to those of partial sleep deprivation and placebo.  Acta Ther. 1995;  21 47-64
    PubMedGoogle Scholar
  • 29 Hindmarch I. Psychomotor function and psychoactive drugs.  Br J Clin Pharmacol. 1980;  10 189-209
    PubMedGoogle Scholar
  • 30 Curran H V. Benzodiazepines, memory and mood: a review.  Psychopharmacology. 1991;  105 1-8
    PubMedGoogle Scholar
  • 31 Bond A J, Lader M H. Residual effects of flunitrazepam.  Br J Clin Pharmacol. 1975;  2 143-150
    PubMedGoogle Scholar
  • 32 Saletu B, Grünberger J, Taeuber K, Nitsche V. Relation between pharmacodynamic and -kinetics: EEG and psychometric studies with cinolazepam and nomifensine. In: Hermann. EEG in Drug Research. Stuttgart, New York: Gustav Fischer 1982: 89-111
    Google Scholar
  • 33 Griffiths A N, Marshall R W, Richens A. Saccadic eye movement analysis as a measure of drug effects on human performance.  Br J Clin Pharmacol. 1984;  18 73S-82S
    PubMedGoogle Scholar
  • 34 Staak M, Hobi V, Berghaus G. Testverfahren zur Überprüfung des Einflusses von Arzneimitteln auf die Verkehrssicherheit - Medizinischer Schwerpunkt. In: Dilling J, Friedel B. 8305/2,. Bergisch Gladbach, Bundesanstalt für Straßenwesen. Forschungsberichte der BASt - Unfallforschung. 1988: 1-195
    Google Scholar
  • 35 Berghaus G. Persönliche Mitteilung. 1998
    Google Scholar
  • 36 Kasper S, Volz H P. Psychiatrie compact. Stuttgart, New York: Georg Thieme Verlag 2003
    Google Scholar
  • 37 Allain H, Patat A, Lieury A, Le Coz F, Janus C, Ménard G, Gandon J M. Comparative study of the effects of zopiclone (7.5 mg), zolpidem, flunitrazepam and a placebo on nocturnal cognitive performance in healthy subjects, in relation to pharmacokinetics.  Eur Psychiatry. 1995;  10 (Suppl 3) 129s-135s
    CrossrefPubMedGoogle Scholar
  • 38 Bareggi S R, Ferini-Strambi L, Pirola R, Smirne S. Impairment of memory and plasma flunitrazepam levels.  Psychopharmacology. 1998;  140 157-163
    CrossrefPubMedGoogle Scholar
  • 39 Ingum J, Bjørklund R, Bjørnboe A, Christophersen A, Dahlin E, Mørland J. Relationship between drug plasma concentrations and psychomotor performance after single doses of ethanol and benzodiazepines.  Psychopharmacology. 1992;  107 11-17
    PubMedGoogle Scholar
  • 40 Smirne S, Ferini-Strambi L, Pirola R, Tancredi O, Franceschi M, Pinto P, Bareggi S R. Effects of flunitrazepam on cognitive functions.  Psychopharmacology. 1989;  98 251-256
    CrossrefPubMedGoogle Scholar
  • 41 Wickstrom E, Godtlibsen O B. The effects of quazepam, triazolam, flunitrazepam and placebo, alone and in combination with ethanol, on day-time sleep, memory, mood and performance.  Hum Psychopharmacol. 1988;  3 101-110
    PubMedGoogle Scholar
  • 42 Linnoila M, Erwin C W, Brendle A, Logue P. Effects of alcohol and flunitrazepam on mood and performance in healthy young men.  J Clin Pharmacol. 1981;  21 430-435
    PubMedGoogle Scholar
  • 43 Kuhlmann J, Berger W, Podzuweit H, Schmidt U. The influence of valerian treatment on “reaction time, alertness and concentration” in volunteers.  Pharmacopsychiatry. 1999;  32 235-241
    PubMedGoogle Scholar
  • 44 Schmidt U, Brendemühl D, Ruther E. Aspects of driving after hypnotic therapy with particular reference to temazepam.  Acta Psychiatr Scand. 1986;  (Suppl 332) 112-118
    PubMedGoogle Scholar
  • 45 Sicard B A, Trocherie S, Moreau J, Vieillefond H, Court L A. Evaluation of zolpidem on alertness and psychomotor abilities among aviation ground personnel and pilots.  Aviat Space Environ Med. 1993;  64 371-375
    PubMedGoogle Scholar
  • 46 Stanley R O, Tiller J WG, Adrian J. The psychomotor effects of single and repeated doses of hypnotic benzodiazepines.  Int Clin Psychopharmacol. 1987;  2 317-323
    PubMedGoogle Scholar
  • 47 Dujardin K, Guieu J D, Leconte-Lambert C, Leconte P, Borderies P, de La Giclais B. Comparison of the effects of zolpidem and flunitrazepam on sleep structure and daytime cognitive functions: A study of untreated unsomniacs.  Pharmacopsychiatry. 1998;  31 14-18
    PubMedGoogle Scholar
  • 48 Rettig H C, Zuurmond W WA, Leeuwen L van. Quality of sleep and psychomotor performance after lormetazepam or flunitrazepam: a randomized and double-blind study.  J Drugtherapy Res. 1988;  13 141-144
    PubMedGoogle Scholar
  • 49 Bensimon G, Foret J, Warot D, Lacomblez L, Thiercelin J F, Simon P. Daytime wakefulness following a bedtime oral dose of zolpidem 20 mg, flunitrazepam 2 mg and placebo.  Br J Clin Pharmacol. 1990;  30 463-469
    PubMedGoogle Scholar
  • 50 Mattmann P, Loepfe M, Scheitlin T, Schmidlin D, Gerne M, Strauch I, Lehmann D, Borbély A A. Day-time residual effects and motor activity after three benzodiazepine hypnotics.  Arzneimittelforschung. 1982;  32 461-465
    PubMedGoogle Scholar
  • 51 Ott H. Are electroencephalographic and psychomotor measures sensitive in detecting residual sequelae of benzodiazepine hypnotics?.  Psychopharmacology. 1984;  (Suppl 1) 133-151
    PubMedGoogle Scholar
  • 52 Seppälä T, Nuotto E, Dreyfus J F. Drug-alcohol interactions on psychomotor skills: Zopiclone and Flunitrazepam.  Pharmacology. 1983;  27 (Suppl 2) 127-135
    PubMedGoogle Scholar
  • 53 Short T G, Galletly D C. Acute tolerance from benzodiazepine night sedation.  Anaesthesia. 1991;  46 929-931
    PubMedGoogle Scholar
  • 54 Frattola L, Maggioni M, Cesana B, Priore P. Double blind comparison of zolpidem 20 mg versus flunitrazepam 2 mg in insomniac in-patients.  Drugs Exp Clin Res. 1990;  XVI 371-376
    PubMedGoogle Scholar
  • 55 Hindmarch I. A repeated dose comparison of three benzodiazepine derivatives (nitrazepam, flurazepam and flunitrazepam) on subjective appraisals of sleep and measures of psychomotor performance the morning following night-time medication.  Acta Psychiatr Scand. 1977;  56 373-381
    PubMedGoogle Scholar
  • 56 Hindmarch I, Parrott A C, Arenillas L. A repeated dose comparison of dichloralphenazone, flunitrazepam and amylobarbitone sodium on some aspects of sleep and early morning behaviour in normal subjects.  Br J Clin Pharmacol. 1977;  4 229-233
    PubMedGoogle Scholar
  • 57 Hofferberth B. Saccadic eye movements as a measure of residual effects: temazepam compared with other hypnotics.  Acta Psychiatr Scand. 1986;  74 (Suppl. 332) 105-111
    PubMedGoogle Scholar
  • 58 Lader M, Melhuish A, Harris P. Residual effects of repeated doses of 0.5 and 1 mg flunitrazepam.  Eur J Clin Pharmacol. 1982;  23 135-140
    CrossrefPubMedGoogle Scholar
  • 59 Charlier C J, Maes V A, Smet H C, Verrstraete A, Wennig R. Influence des médicaments sur les capacités de conduite - Etude de la littérature. In: van Den Meersschaut C. 1. Brussel, Institut Belge pour la Sécurité Routiére asbl. 1999 (IBSR)
    Google Scholar
  • 60 Kaufmann R M. Medikamente und Fahrtüchtigkeit - Klassifizierung von Benzodiazepinderivaten nach pharmakologischen und verkehrsmedizinischen Gesichtspunkten. Dissertation, Institut für Gerichtliche Medizin der Leopold-Franzens-Universität Innsbruck. 2002: 1-220
    Google Scholar
  • 61 Darcourt G, Pringuey D, Salliere D, Lavoisy J. The safety and tolerability of zolpidem - an update.  J Psychopharmacol. 1999;  13 81-93
    PubMedGoogle Scholar
  • 62 DeClerk A C, Bisserbe J C. Short-term safety profile of zolpidem: objective measures of cognitive effects.  Eur Psychiatry. 1997;  12 (Suppl 1) 15s-20s
    CrossrefPubMedGoogle Scholar
  • 63 Lader M, Hindmarch I. Memory, psychomotor and cognitive functions after treatment with zolpidem. In: Freeman H, Puech AJ, Roth T. eds.: Zolpidem an update of its pharmacological properties and therapeutic place in the management of insomnia. Paris: Elsevier 1996: 59-71
    Google Scholar
  • 64 Unden M, Roth Schechter B. Next day effects after nighttime treatment with zolpidem: A review.  Eur Psychiatry. 1996;  11 (Suppl. 1) 21S-30S
    CrossrefPubMedGoogle Scholar
  • 65 Greenblatt D J, Divoll M, Harmatz J S, Mac Laughlin D S, Shader R I. Kinetics and clinical effects of flurazepam in young and elderly noninsomniacs.  Clin Pharmacol Ther. 1981;  30 475-486
    CrossrefPubMedGoogle Scholar
  • 66 Greenblatt D J, Harmatz J S, Shapiro L, Engelhardt N, Gouthro T A, Shader M D. Sensitivity to triazolam in the elderly.  N Engl J Med. 1991;  324 1691-1698
    CrossrefPubMedGoogle Scholar
  • 67 Ray W A, Thapa P B, Shorr R I. Medications and the older driver.  Clin Geriatr Med. 1993;  9 413-438
    PubMedGoogle Scholar
  • 68 Roth T, Ancoli-Israel S. Daytime consequences and correlates of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. II.  Sleep. 1999;  Suppl 2 S354-S358
    PubMedGoogle Scholar
  • 69 Ellinwood E H, Heatherly D G. Benzodiazepines, the popular tranquilizers: Dynamic of effect on driving skills.  Accid Anal Prev. 1985;  17 283-290
    CrossrefPubMedGoogle Scholar
  • 70 Kunsman G W, Manno J E, Manno B R, Kunsman C M, Przekop M A. The use of microcomputer-based psychomotor tests for the evaluation of benzodiazepine effects on human performance: a review with emphasis on temazepam.  Br J Clin Pharmacol. 1992;  34 289-301
    PubMedGoogle Scholar
  • 71 Bramness J G, Skurtveit S, Mørland J. Clinical impairment of benzodiazepines-relation between benzodiazepine concentrations and impairment in apprehended drivers.  Drug Alcohol Depend. 2002;  68 131-141
    CrossrefPubMedGoogle Scholar
  • 72 de Gier J J. Driving tests with patients.  Br J Clin Pharmacol. 1984;  18 103S-108S
    PubMedGoogle Scholar
  • 73 Ramaekers J G, Veggel L M van, O'Hanlon J F. A cross-study of the effects of moclobemide and brofaromine on actual driving performance.  Clin Neuropharmacol. 1994;  17 (Suppl 1) S9-S18
    PubMedGoogle Scholar
  • 74 Volkerts E R, Vries G de, Wiethof M, Meyer T, O'Hanlon J F. Loprazolam and flunitrazepam's residual effects upon actual driving performance. Technical Report VK 83 - 04. University of Groningen, Netherlands: Traffic Research Centre 1983
    Google Scholar
  • 75 Volkerts E R, Louwers J W, Gloerich A BM, Brookhuis K J, O'Hanlon J F. Zopiclone's residual effects upon actual driving performance versus those of nitrazepam and flunitrazepam. Technical Report VK 84 - 10. University of Groningen, Netherlands: Traffic Research Centre 1984
    Google Scholar
  • 76 Irving A, Jones W. Methods for testing impairment of driving due to drugs.  Eur J Clin Pharmacol. 1992;  43 61-66
    PubMedGoogle Scholar
  • 77 Stone B I. Pencil and paper tests-sensitivity to psychotropic drugs.  Br J Clin Pharmacol. 1984;  18 15S-20S
    PubMedGoogle Scholar
  • 78 Hindmarch I, Ott H, Roth T. Sleep, benzodiazepines and performance. “Experimental Methodologies and Research Prospects”. Heidelberg: Springer Verlag 1984
    Google Scholar
  • 79 Wittenborn J R, Flaherty C F, Hamilton L W, Schiffman R T, McGough W E. The effect of minor tranquilizers on psychomotor performance.  Psychopharmacology. 1976;  47 281-286
    CrossrefPubMedGoogle Scholar
  • 80 Berghaus G, Staak M. Testverfahren zur Überprüfung des Einflusses von Arzneimitteleinnahme auf die Fahrsicherheit.  Beitr Gerichtl Med. 1988;  46 67-70
    PubMedGoogle Scholar
  • 81 Ferrara S D. Quality assurance and standardization of empirical trials on drugs and driving. Proceedings of the 12th international conference on alcohol, drugs and traffic safety. Köln 1992
    Google Scholar

Dr. Rainer Marco Kaufmann

Klinische Abteilung für Allgemeine Psychiatrie · Univ.-Klinik für Psychiatrie · Medizinische Universität Wien

Währinger Gürtel 18 - 20

1090 Wien

Österreich

Email: rainer.kaufmann@akhwien.at

      >